Piramal Pharma Limited released its Sustainability Report 2025–26, reporting its lowest-ever Scope 1 and Scope 2 emissions as it advances an SBTi-approved decarbonisation roadmap. Emissions fell 22.6% from the FY2022 baseline, renewable energy reached 41% of total energy consumption, 2.63 Lakh kilolitres of freshwater were recycled and reused, and 65% of total waste was diverted for recycling. The company completed 38 regulatory inspections, including three USFDA inspections with zero Official Action Indicated observations, and 209 customer audits. It also advanced digital transformation through Catalyst NxGen, SAP S/4HANA and digital quality systems, while announcing a US$90 million investment to expand advanced therapeutics capabilities at its Lexington and Riverview facilities. Piramal Pharma reported zero data breaches and corruption cases, 100% ESG and Code of Conduct training completion, women comprising 30% of the Board and 20.1% of its global workforce, and sustainability assessments covering 38% of critical suppliers. During FY2025–26, it invested ₹8.98 crore in CSR initiatives that reached nearly 1.8 million people across 112 Aspirational Districts through healthcare and education programmes. The sustainability framework is organized around Business Resilience, Quality & Excellence, Responsible Operations and Stakeholder Centricity, with more than 50 time-bound targets across 17 material topics. The report follows GRI standards and aligns with SASB and UNGC frameworks, with oversight from the Sustainability and Risk Management Committee.